Page 2 - Pharma Industry

Sudeep Pharma IPO subscribed 5.09 times on Day 2; NII bids hit 12x

The initial public offer of Sudeep Pharma Ltd received 5.09 times subscription on the second day of bidding on Monday. The IPO received bids for 5,37,83,650 shares against 1,05,64,926 shares on offer, according to NSE data. The category for non-institutional investors fetched 12 times subscription, while the quota for Retail Individual Investors (RIIs) got subscribed 4.96 times. The Qualified Institutional Buyers (QIBs) portion received 13 per cent subscription. Sudeep Pharma on Thursday said it has mobilised Rs 268.5 crore from anchor investors. The Rs 895 crore initial public offering (IPO) will conclude on Tuesday. The price band has been fixed at Rs 563-593 per equity share. The IPO has a fresh issue of equity shares worth Rs 95 crore and an offer-for-sale of nearly 1.35 crore equity shares, aggregating to Rs 800 crore, by the promoters. Proceeds from the fresh issue to the tune of Rs 75.81 crore will be used for capital expenditure towards the procurement of machinery for it

Drug regulator mandates CDSCO licensing on medical device procurement

The regulator told states not to demand USFDA or EU approvals in tenders after complaints that Indian-made devices were being sidelined

Mankind Pharma inks licencing pact with Actimed for cachexia treatment

Mankind Pharma has entered a licensing agreement with Actimed Therapeutics to develop and commercialise cachexia treatment products across India and neighbouring South Asian markets

Akums Q2 PAT falls 35.8% on muted CDMO biz growth, declining API prices

Despite this, the CDMO segment remained Akums' key growth driver, contributing Rs 804 crore, or 79 per cent of its total revenue

Servier India launches subsidised biomarker tests for rare cancers

Servier India has tied up with MedGenome and Reliance-backed Strand Life Sciences to offer low-cost IDH1 and IDH2 biomarker testing for rare cancers like AML and CCA across India

Emcure Pharma Q2 results: PAT rises 25% to ₹251 crore on strong sales

Emcure Pharmaceuticals on Tuesday reported a 25 per cent increase in profit after tax to Rs 251 crore in the September quarter, aided by strong sales performance across domestic and export markets. The drug firm posted a profit after tax (PAT) of Rs 202 crore during the July-September quarter of the last fiscal. Revenue from operations rose to Rs 2,270 crore in the second quarter as against Rs 2,002 crore in the year-ago period, Emcure Pharmaceuticals said in a statement. "We continue to augment our portfolio in all our focus markets through in-licensing and in-house developments. Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry, enabling us to shape the market, Emcure Pharmaceuticals Chief Executive Officer and Managing Director Satish Mehta said. The company remains focused on delivering strong growth along with margin improvement in all key businesses, he added. Shares of the company were trading 3.90 per cent down at Rs

Novo Nordisk, Emcure Pharmaceuticals tie up to expand Wegovy's girth

2.4 mg injectable Poviztra to mark next phase of weight-loss rollout

Pharma units likely to face action for Schedule M violations: Experts

The one-year grace period for MSME drug manufacturers to comply with revised Schedule M norms has ended, with the CDSCO instructing state regulators to initiate inspections & action against violators

Mounjaro India's bestselling drug in October with ₹100 crore sales

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind

Rebound in US biopharma funding may boost orders, says Piramal Pharma

The drugmaker's revenue fell 9% in Q2FY26 on below-par CDMO performance; company says it faced inconsistent funding in H1FY26

Mankind Pharma Q2 PAT drops 21% on high finance costs; revenue up 20%

Mankind Pharma's Q2 FY26 profit fell to Rs 520 crore on higher finance and input costs, even as strong domestic and export growth lifted revenue by over 20%.

NPPA fixes retail price of 28 drugs, ceiling price of six formulations

The National Pharmaceutical Pricing Authority has revised retail prices of 28 formulations and capped ceiling prices for six drugs under the National List of Essential Medicines

Lupin Q2 PAT rises 73% on strong growth across key global markets

Lupin's consolidated profit rose 73% YoY to Rs 1,478 crore in Q2 FY26, led by robust sales in India and the US and higher margins from an improved product mix

Alembic Pharma Q2 profit rises 21% on robust US generics and API growth

Alembic Pharma's consolidated profit rose 21% to Rs 185 crore in Q2 FY26, led by strong performance in US generics, APIs, and international markets, with six new ANDA approvals

Gland Pharma Q2 results: Profit rises 12% on recovery at Europe's Cenexi

The consolidated net profit rose to 1.84 billion rupees (nearly $21 million) for the quarter ended September 30 from 1.64 billion rupees a year earlier

Achin Gupta to succeed Umang Vohra as Cipla MD & GCEO from April 2026

Umang Vohra joined Cipla in 2015 as global chief financial and strategy officer and thereafter served as the company's MD & GCEO since 2016

Centre brings draft rules to debar drugmakers who provide fake information

The health ministry proposes new provisions under the Drugs Rules, 1945, allowing regulators to bar applicants who submit fake or misleading data for approvals

Cough syrup deaths: CDSCO launches digital tracker for high-risk solvents

The regulator's ONDLS-based monitoring platform will track supply chains and quality of solvents used in drug manufacturing following child deaths linked to toxic cough syrups

Biocon Biologics gets Health Canada approval for Yesintek, Yesintek I.V.

The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio

Lilly and Cipla to market tirzepatide in India under new brand Yurpeak

The Lilly-Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and obesity care across urban and semi-urban markets